News | February 22, 2022
IFF to acquire contract manufacturer of dietary supplements Health Wright Products
The sale is expected to close in the first quarter of 2022
The sale is expected to close in the first quarter of 2022
Urban, semi-urban and remote corners of the country will be catered using drone delivery technology
Takes charge to lead business innovation, strategy, alliance & partnerships
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
It plans to add over 1000 employees over the next six months
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Subscribe To Our Newsletter & Stay Updated
